Abstract
Abstract Coumarin-benzothiazole hybrids are antitumor agents based on their antioxidant and α-glucosidase inhibitory activities. Compounds 5a–c were selected by National Cancer Institute (NCI), USA, to be screened for antitumor activity at a single dose (10 μm) against a panel of 60 cancer cell lines. The most active compound 5c was further screened at a five-dose level by NCI. Compound 5c displays half maximal growth inhibition (GI50) values of 0.24 and 0.33 μm against central nervous system (CNS) cancer (SNB-75) and ovarian cancer (OVCAR-4) cell lines, respectively. Compounds 5a–c were also screened for their antioxidant and α-glucosidase inhibitory activities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
